Details of the Drug Combination

General Information of Drug Combination (ID: DCOUV8I)

Drug Combination Name
Azithromycin Cefixime
Indication
Disease Entry Status REF
Vaginitis Bacterial Phase 1 [1]
Component Drugs Azithromycin   DMS6UOE Cefixime   DMY60I8
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL is unavailable 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Azithromycin
Disease Entry ICD 11 Status REF
Acute gonococcal cervicitis N.A. Approved [2]
Bronchitis CA20 Approved [3]
Chancroid N.A. Approved [2]
Mycoplasma pneumoniae pneumonia N.A. Approved [2]
Staphylococcus aureus infection N.A. Approved [2]
Streptococcal pneumonia N.A. Approved [2]
Coronavirus Disease 2019 (COVID-19) 1D6Y Phase 3 [4]
Pneumonia caused by chlamydia N.A. Investigative [2]
Indication(s) of Cefixime
Disease Entry ICD 11 Status REF
Acute gonococcal cervicitis N.A. Approved [5]
Acute otitis media AB00 Approved [5]
Bacterial infection 1A00-1C4Z Approved [6]
Bronchitis CA20 Approved [5]
Cervicitis N.A. Approved [5]
Pars planitis N.A. Approved [5]
Respiratory tract infection CA45 Approved [5]
Urinary tract infection GC08 Approved [5]
Cefixime Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Bacterial Penicillin binding protein (Bact PBP) TTJP4SM NOUNIPROTAC Binder [7]
------------------------------------------------------------------------------------
Cefixime Interacts with 2 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
Peptide transporter 1 (SLC15A1) DT9G7XN S15A1_HUMAN Substrate [8]
Peptide transporter 2 (SLC15A2) DT8QKNP S15A2_HUMAN Substrate [9]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT01072136) Empiric Therapy of Mucopurulent Cervicitis (MPC)
2 Azithromycin FDA Label
3 FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (ANDA) 065511.
4 ClinicalTrials.gov (NCT04332107) Azithromycin for COVID-19 Treatment in Outpatients Nationwide. U.S. National Institutes of Health.
5 Cefixime FDA Label
6 Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
7 Genetics of chromosomally mediated intermediate resistance to ceftriaxone and cefixime in Neisseria gonorrhoeae. Antimicrob Agents Chemother. 2009 Sep;53(9):3744-51.
8 Flavonoids with epidermal growth factor-receptor tyrosine kinase inhibitory activity stimulate PEPT1-mediated cefixime uptake into human intestinal epithelial cells. J Pharmacol Exp Ther. 2001 Oct;299(1):351-7.
9 Transport characteristics of a novel peptide transporter 1 substrate, antihypotensive drug midodrine, and its amino acid derivatives. J Pharmacol Exp Ther. 2006 Jul;318(1):455-60.